AMRX
Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

4,037
Mkt Cap
$4.56B
Volume
1.53M
52W High
$15.42
52W Low
$6.69
PE Ratio
1,021.13
AMRX Fundamentals
Price
$14.50
Prev Close
$14.60
Open
$14.60
50D MA
$13.44
Beta
1.11
Avg. Volume
3.6M
EPS (Annual)
-$0.3783
P/B
-41.64
Rev/Employee
$336,621.33
$4,986.55
Loading...
Loading...
News
all
press releases
Collegium Pharmaceutical to Report Q4 Earnings: What's in the Cards?
COLL gears up to report Q4 earnings. Strong Jornay PM demand and higher pain portfolio sales fuel investor expectations ahead of its Feb. 26 report.
Zacks·3d ago
News Placeholder
More News
News Placeholder
Amneal Pharmaceuticals (NASDAQ:AMRX) Sets New 52-Week High - Should You Buy?
Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 12-Month High - Time to Buy...
MarketBeat·5d ago
News Placeholder
Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market
Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market PR Newswire VANCOUVER, BC, Feb. 13, 2026...
PR Newswire·9d ago
News Placeholder
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of "Moderate Buy" by Brokerages
Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the five analysts that are currently covering the company...
MarketBeat·9d ago
News Placeholder
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Up 87.3% in January
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) was the target of a large growth in short interest in January. As of January 30th, there was short interest totaling 12,685,342 shares, a...
MarketBeat·9d ago
News Placeholder
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
Here is how ALX Oncology Holdings Inc. (ALXO) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
Zacks·13d ago
News Placeholder
Mettler-Toledo Q4 Earnings Top Estimates, Sales Rise Y/Y
MTD beats Q4 estimates as adjusted EPS jumps 8% Y/Y and sales rise to $1.13B, led by solid growth across Laboratory, Industrial and Food Retail.
Zacks·16d ago
News Placeholder
Is Amneal Pharmaceuticals (AMRX) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks·17d ago
News Placeholder
IQVIA Set to Report Q4 Earnings: Here's What You Should Know
IQV is set to report fourth-quarter 2025 earnings results on Feb. 5, with revenues expected to rally 7.2% y/y to $4.2B and EPS to rise 9% on segment growth.
Zacks·19d ago
News Placeholder
AustralianSuper Pty Ltd Makes New Investment in Amneal Pharmaceuticals, Inc. $AMRX
AustralianSuper Pty Ltd acquired a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and...
MarketBeat·22d ago
<
1
2
...
>

Latest AMRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.